35 results
Thumbnail

D1.90 - Remission of asthma on biological therapy: one center experience

Thumbnail

D1.98 - MV130 drives the differentiation of human monocytes into dendritic cells with antiallergic properties

Thumbnail

D1.102 - Md

Thumbnail

D1.88 - Mepolizumab and intestinal parasitic infection: A case report

Thumbnail

D1.91 - Baseline characteristics and main clinical outcomes of patients receiving tezepelumab in the framework of use in Special Situations prior to commercialization in Spain (T-ROSS Study)

Thumbnail

D1.92 - Results from the EGPAware Delphi study on Red Flags for Suspicion of Eosinophilic Granulomatosis with Polyangiitis (EGPA): current management in Europe

Thumbnail

D1.93 - ICS use trajectories in severe asthma patients on benralizumab: real-life data from 3-years follow-up

Thumbnail

D1.94 - Impact of overweight and obesity on clinical remission and Response to Biologics in Severe Asthma Patients

Thumbnail

D1.95 - Dupilumab-induced eosinophilia: a transient effect

Thumbnail

D1.96 - Impact of Dupilumab-induced Eosinophilia on Pulmonary Function Tests and Patient Reported Outcomes Measures (PROMs)

Thumbnail

D1.99 - Exploring the relationship between 6 minutes walk test (6MWT) performance and lung function in Severe Asthma and CRSwNP

Thumbnail

D1.370 - Clinical outcomes and quality of life improvement in children with moderate-to-severe atopic dermatitis and atopic multimorbidity treated with dupilumab

Thumbnail

D1.362 - Exploratory Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of YH35324, a Long-Acting high-affinity IgETrap-Fc protein, in Patients with Chronic Spontaneous Urticaria Refractory to Omalizumab

Thumbnail

D1.363 - Efficacy and safety of Mepolizumab in treatment of eosinophilic granulomatosis with polyangiitis

Thumbnail

D1.364 - Update on the Observed incidence of Anaphylaxis and Serum Sickness in Patients Receiving Omalizumab in a Canadian Tertiary Allergy/Asthma Clinic

Thumbnail

D1.365 - ZL-1503: A Bispecific Antibody Targeting Inflammatory and Pruritogenic Pathways with a Prolonged Serum Half-life and Sustained Activity in Non-human Primates

Thumbnail

D1.366 - Improvement Over Time in Specific Aspects of Quality of Life in Patients with Chronic Spontaneous Urticaria Treated with Omalizumab

Thumbnail

D1.367 - Dupilumab for refractory pruritus in hematological and non-hematological malignancies – preliminary results

Thumbnail

D1.368 - Anti-interleukin-5 treatment in patients with severe eosinophilic asthma provides consistent symptom control for at least 8 years

Thumbnail

D1.369 - Characteristics of patients with severe asthma undergoing biological treatment at a reference center